Shares of Baxter International (BAX) have gained 2.4% in the first seven trading sessions in July after declining 13.5% in the first six months of 2024.The decline in BAX’s shares during the first half can be attributed to challenges, including inflationary pressure and weaker ESRD patient volume in China due to the residual impact of COVID-19. Moreover, China’s value-based procurement initiatives are lowering realized price for the company’s products in the country.Meanwhile, the recovery in Baxter’s share ...